Our story

THE DCCC ctDNA RESEARCH CENTER

In January 2020 the Danish Cancer Society establised The Danish National Center for Circulating Tumor DNA Guided Cancer Treatment in collaboration with DCCC - Danish Comprehensive Cancer Center. The ctDNA Research Center is supported by funds from 'Knæk Cancer' and works to strengthen the Danish national collaboration in ctDNA cancer research - for the benefit of every cancer patients in Denmark.

Our values

ESSENSE OF THE CENTER

National collaboration
Knowledge sharing
Achieving synergy
Individual treatment
Faster implementation

The DCCC ctDNA Research Center is a national founded research center for ctDNA guided cancer treatment

The center is founded on national collaboration

The DCCC ctDNA Research Center is a national founded research center for ctDNA guided cancer treatment

In January 2020 the Danish National Center for Circulating Tumor DNA Guided Cancer Treatment was establishedThe objective of the center is to provide an effective and vital framework for optimal implementation of evidence-based ctDNA usage in cancer patient management in Denmark.

National collaboration 

With the center all Danish clinicians and researchers with an interest in using ctDNA based analysis for monitoring and decision making are brought together to facilitate ctDNA based research and clinical implementation of ctDNA guided patient stratification. National collaboration is in the core of the center.

From research to clinic 

The cancer field is lacking biomarkers for personalized risk-stratification. Consequently clinical practice today is dominated by “one size fits all” strategies e.g. for treatment-and post-treatment surveillance. This is often leading to massive overtreatment and a waste of resources following up non-relapsing patients.

The center aims to offer participation in evidence generating clinical trials to all relevant Danish cancer patients. Such trials will explore the clinical utility of using ctDNA for e.g. detection of cancer in asymptomatic individuals, post-operative detection of residual disease to guide adjuvant treatment decisions, detection of residual disease after adjuvant therapy in order to guide imaging surveillance intensity, for blood-based recurrence surveillance, for monitoring therapy response (neoadjuvant, adjuvant and in treatment of metastatic disease), detection of actionable targets for guiding therapy choice etc.

If the results confirm our hypotheses: that ctDNA guided management has clinical benefit compared to the present standard, and that ctDNA guided management is cost-effective, then we shall provide business analyses and other decision and implementation supporting information to the hospitals and health regions. We anticipate timely and relatively straight forward implementation of ctDNA guided cancer management at a national scale in Denmark, since the conducted studies will be national with participation from the majority of the clinical centers treating cancer patients in Denmark.

Mission

To promote and facilitate ctDNA research, clinical trails, and translation into clinical practice

To make the clinical benefits of ctDNA guided clinical decision-making available to all Danish cancer patients regardless of where in the country they live and no matter what type of cancer they have

Vision

To be able to give the right treatment at the right moment to the right person - individual treatment




Image
National collaboration

INVOLVED DEPARTMENTS

Our organization

It takes all of us to make a national collaboration

CENTER PARTICIPANTS

The members are from different universitites and hospitals all over Denmark - working with research in ctDNA guided cancer treatment. We have participation from all the departments involved in management of cancer patients e.g. Surgery, Pathology, Oncology, Radiology, Nuclear medicin, Genomic medicine, and Molecular Medicine. It is a multidisciplinary research center.

 
 

STEERING COMMITTEE

The center have a Steering Committee with one representative from each of the participating departments. The Steering Committee ensures a broad scientific and clinical anchoring of all the center activities in the different departments and institutions involved - and they make decisions on behalf of the center.

EXECUTIVE COMMITTEE

Among the members of the Steering Committee, an Executing Committee has been apointed. The Executing Committee prepare matters for consideration in the Steering Committee. There is a geographical and scientific broadness in this committee.

CENTER MANAGEMENT

Professor Claus Lindbjerg Andersen is Center Director and Professor Lars Dyrskjøt Andersen is Center Vice Director. Together with Scientific Coordinator Anne Lærke Lorentzen the center management is responsible for the daily running and facilitation of the tasks in the center.

Image
Our foundation

SUPPORT

The ctDNA Research Center is part of the Danish Comprehensive Cancer Center, who is a national, binding collaboration on cancer research and treatment, and gathers professional experts in the field of cancer. The ctDNA center is supported by the Danish Cancer Society.

Thank you for the collaboration!

Image
Image

What is ctDNA?

Read about circulating tumor DNA

The research

Read about funded projects and publications

CFA and NI

Read about the activities in the CFA's and NI's

Contact

Find the contact information here
NEED TO GET IN TOUCH?

Do you have any questions, need help to find an expert, or want to be affiliated with the ctDNA center?